Ex­clu­sive: Har­vard start­up rais­es $26M, strikes three phar­ma part­ner­ships for AI an­ti­body de­sign

Last year
Deals
AI

Ama­zon vet­er­an Mis­sy Kras­ner shares why now is the time for young health star­tups to go shop­ping

Last year
Health Tech

Pfiz­er sub­mits trade­mark ap­pli­ca­tion that sug­gests it could be launch­ing a di­rect-to-pa­tient pro­gram

Last year
Pharma
Health Tech

Ab­b­Vie goes deep­er in­to neu­ro­science with col­lab­o­ra­tion worth as much as $2B

Last year
Deals
Pharma

WHO mem­bers miss dead­line for pan­dem­ic ac­cord draft, will con­tin­ue talks

Last year
Pharma
FDA+

Sh­iono­gi miss­es pri­ma­ry end­point in Phase 3 for Covid-19 an­tivi­ral

Last year
R&D
Coronavirus

Size of 340B mar­ket triples since 2018 and may dou­ble again, re­port says

Last year
Pharma

No­vo clears Phase 3 he­mo­phil­ia A tri­al, plans to sub­mit ap­pli­ca­tion by year's end

Last year
R&D

Car­du­ri­on touts Phase 2 da­ta for PDE9 in­hibitor in heart fail­ure, plans for two more tri­als

Last year
R&D

De­ci­phera had an­oth­er bid­der be­fore Ono deal; Bris­tol My­ers re­ports Ph3 fail in lung can­cer

Last year
News Briefing

Cy­to­ki­net­ics lifts cur­tain on Phase 3 afi­camten da­ta, com­mer­cial launch prep un­der­way

Last year
R&D
Pharma

Mer­ck winds down Phase 3 TIG­IT/PD-1 com­bo study due to safe­ty-re­lat­ed dropouts

Last year
R&D

Take­da bets $100M up­front on AC Im­mune's an­ti-amy­loid Alzheimer's vac­cine

Last year
Deals
Pharma

Car­olyn Bertozzi-found­ed Ly­cia Ther­a­peu­tics rais­es $106M to en­ter the clin­ic

Last year
Financing
Startups

New­Vale un­veils $167M fund to back phar­ma ser­vice providers and 'old ideas that are work­ing'

Last year
Financing
Outsourcing

'At­tack JAK': Ajax se­cures $95M to test new JAK2 in­hibitor af­ter in­dus­try's string of myelofi­bro­sis deals

Last year
Financing
Startups

Trail­blaz­ers, icon­o­clasts and break­through artists are com­ing to the End­points biotech sum­mit — please join us

Last year
Bioregnum

Sanofi buys ex-US rights to Ful­crum's Phase 3 rare neu­ro­mus­cu­lar drug

Last year
Deals
Pharma

Up­dat­ed: France draws €2B+ re­search, man­u­fac­tur­ing in­vest­ment from Sanofi, Pfiz­er, As­traZeneca, GSK

Last year
Financing
Manufacturing

Top sto­ries from cell/gene ther­a­py con­fab; 2032 dead­line to de­cou­ple; Pa­tient death in Pfiz­er tri­al; and more

Last year
Weekly

New Biose­cure draft fea­tures 2032 grand­fa­ther clause, five-year grace pe­ri­od for added com­pa­nies

Last year
China
Pharma

Sen­a­tors ques­tion Cham­ber of Com­merce's mo­tives around march-in rights

Last year
Pharma
FDA+

House Re­pub­li­cans put pres­sure on AS­PR’s man­age­ment of the na­tion­al drug stock­pile

Last year
Pharma
Law

Ex­ci­sion Bio­Ther­a­peu­tics’ at­tempt to gene ed­it HIV dis­ap­points. The com­pa­ny will now re­vamp vec­tor: #AS­GCT24

Last year
R&D
Cell/Gene Tx
First page Previous page 158159160161162163164 Next page Last page
A service from the Financial Times